Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:2134-2141.

Slides:

Advertisements

Similar presentations

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Advertisements

Rational, Trial Design, and Results of the ADAGIO Delayed Start Trial C. Warren Olanow, MD, FRCPC Henry P. and Georgette Goldschmidt Professor Chairman.

Trial profile Fox K et al. Lancet 2008;372:

Trial Identification, Inclusion, and Exclusion Krista M. Dale et al, JAMA. 2006; 295:

Slide Source: Lipids Online Slide Library Heart and Estrogen/progestin Replacement Study (HERS) and HERS II: Secondary Prevention.

ASTEROID A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound- Derived coronary atheroma burden.

Philip J. Barter, et al. Circulation 2011;124:

Antiplatelet Therapy Use and the Risk of Venous Thromboembolic Events in the Double-Blind Raloxifene Use for the Heart (RUTH) Trial C. Duvernoy 1, A. Yeo.

The TRial Of Preventing HYpertension (TROPHY) TROPHY.

Flow of Participants Through the Trial David J. A. Jenkin et al. JAMA 2008;300:

Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,

Solomon Tesfaye et al N Engl J Med 2005;352: Comparison of Baseline Data in 1819 Patients According to Whether There Was an Assessment for Neuropathy.

Enrollment and Outcomes Fan Fan Hou, et al. N Engl J Med 2006;354:

Enrollment, Randomization, and Follow-up of Study Participants ADVANCE Collaborative Group. N Engl J Med 2008;358:

Patient disposition Dichtl W, et al. Am J Cardiol. 2008;102:743-8 AVR = aortic valve replacement; MDCT = multidetector computed tomographic.

High-dose ARB monotherapy versus ARB/CCB combination on cardiovascular events in Japanese elderly high-risk hypertensive patients. The OSCAR trial Ogawa.

Baseline Patient Characteristics Bart A.N. Verhoeven, et al. Stroke 2006;37:

Hsia J et al. J Am Coll Cardiol 2011;57: Baseline Characteristics by Treatment Group and Attained LDL-C Hsia J et al. J Am Coll Cardiol 2011;57:

Shalev V, et al. Arch Intern Med 2009; 169:

1 CONFIDENTIAL – DO NOT DISTRIBUTE ARIES mCRC: Effectiveness and Safety of 1st- and 2nd-line Bevacizumab Treatment in Elderly Patients Mark Kozloff, MD.

Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:

Trial profile Prakash Deedwania, et al. Lancet 2006; 368:

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Trial profile Mann JF et al. Lancet 2008;372:

Number of participants with diabetes by trial Cholesterol Treatment Trialists' (CTT) Collaborators Lancet 2008;371:

Characteristics of studies on lifestyle interventions included in review Gillies CL, et al. BMJ 2007;334:

Date of download: 6/21/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Low-Dose Aspirin for Primary Prevention of Cardiovascular.

Flow Diagram of the Trial Selection Process Jeffrey S. Berger et al, JAMA. 2006;295:

Baseline Mean Daily Servings of Coffee and Other Beverages and of Caffeine in Women in the Iowa Women’s Health Study, 1986* *Data are given as.

Low-Dose Aspirin for Primary Prevention of Cardiovascular Events in Patients With Diabetes: A Meta-Analysis Stavros Stavrakis, MD The American Journal.

Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:

All-cause mortality by treatment group

Mancia and Grassi (2018) Diabetologia DOI /s

Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:

A New Era for NOACs:.

Figure 3 Ischaemic outcomes in the ST-segment elevation myocardial

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

Aspirin and Cardioprevention in 2018

Hajer GR et al. Atherosclerosis 2009;202:216-24

Enrollment and Outcomes

Relative risks of clinical events for primary and secondary prevention with selected drugs Thomas A Gaziano, et al. Lancet 2006; 368:

Figure 1 Relationships between magnitude of antithrombotic benefit vs

Berger JS, et al. JAMA 2009;301:

Flow of Patients Through the Trial

Baseline Characteristics According to Sex

Flow of Patients Through Trial

Study Participant Flow

Flow Diagram of the Trial Selection Process

Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:

Baseline Characteristics of the Study Participants

Baseline Characteristics, Blood Pressures, and Laboratory Values

Baseline characteristics for patients with diabetes in ASCOT-LLA Part I P.S. SEVER et al Diabetes Care 2005; 28: 1151–1157.

Women’s Health Study: Baseline Characteristics Part 1

Jeffrey S. Berger, et al. Circ Cardiovasc Qual Outcomes 2009;2:78-87

Patient Disposition James A. de Lemos et al. JAMA 2004; 292:

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.

Baseline characteristics of older women (NHS I), younger women (NHS II), and men (HPFS) with a history of hypertension according to thiazide use Eric N.

Baseline Characteristics by hs-CRP

The ACCORD Study Group. NEJM 2010; Epub March 14

Brugts JJ, et al. BMJ 2009;338:b2376.

A: Relative risk of experiencing one or more hypoglycemic events per participant at any time (24 h) and during the night (0000–0559 h) for Gla-300 vs.

Baseline demographics and clinical characteristics of 3,956 rosuvastatin-treated patients Donald G. Vidt, et al. Am J Cardiol 2006;97:1602–1606.

Flow of study participants

Percentage of weight loss over 5 years in response to 12-week intensive lifestyle intervention in a real-world clinical practice. Percentage of weight.

Flow diagram illustrating diabetes outcomes in the randomly assigned treatment of folic acid and vitamins B6 and B12 of the WAFACS. A total of 1,190 participants.

Incidences of transitions between glycemic states by 25-OHD level.

Meta-analysis of trials examining the effects of aspirin on risk of CVD events in patients with diabetes. Meta-analysis of trials examining the effects.

Translating Data From Trial to Practice

Presentation transcript:

Participation in Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes (JPAD) Trial Hisao Ogawa et al. JAMA 2008;300:2134-2141

Baseline Clinical Characteristics – Part I Hisao Ogawa et al. JAMA 2008;300:2134-2141

Baseline Clinical Characteristics – Part II Hisao Ogawa et al. JAMA 2008;300:2134-2141

Atherosclerotic Events Hisao Ogawa et al. JAMA 2008;300:2134-2141

Total Percentage of Atherosclerotic Events According to Treatment Group Hisao Ogawa et al. JAMA 2008;300:2134-2141

Subgroup Analysis of Incidence of Atherosclerotic Events Hisao Ogawa et al. JAMA 2008;300:2134-2141

Adverse Effects Hisao Ogawa et al. JAMA 2008;300:2134-2141